Patient‐reported symptoms of eczema · children and adults with mild to severe eczema
Moderate‐potency may leads to lower patient‐reported symptoms of eczema: 1‐5 weeks compared with mild‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Clinician‐reported signs of eczema · people with eczema
1 finding from 1 review
Patient‐reported symptoms of eczema · people with eczema
1 finding from 1 review
Adverse effects: local · people with eczema
1 finding from 1 review
Systemic adverse events at · people with eczema
1 finding from 1 review
Clinician‐reported signs of eczema: number of participants with one or more relapses (16‐20 weeks) · children and adults with mild to severe eczema
Weekend therapy probably leads to lower clinician‐reported signs of eczema: number of participants with one… compared with no topical corticosteroid (moderate certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults with mild to severe eczema
Weekend therapy probably leads to higher patient‐reported symptoms of eczema: PGA (number judging… compared with no topical corticosteroid (moderate certainty).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (16‐20 weeks + 2‐4 weeks acute phase) · children and adults with mild to severe eczema
Weekend therapy may leads to lower local adverse events: skin thinning; end of treatment (16‐20 weeks +… compared with no topical corticosteroid (low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (16 weeks + 4 weeks acute phase) · children and adults with mild to severe eczema
It is very uncertain whether weekend therapy changes systemic adverse events: abnormal cortisol; end of treatment (16… compared with no topical corticosteroid (very low certainty).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults with mild to severe eczema
Moderate‐potency may leads to lower local adverse events: skin thinning; end of treatment (2‐5 weeks) compared with mild‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
It is very uncertain whether moderate‐potency changes systemic adverse events: abnormal cortisol; end of treatment (6‐28… compared with mild‐potency topical corticosteroid (very low certainty).
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults with mild to severe eczema
Potent probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults with mild to severe eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (16‐20 weeks + 2‐4 weeks acute phase) · children and adults with mild to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema
Potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with moderate‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Intervention not reported
Total studies: 8 RCTs Total Participants: 9983 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
Severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 812(1 RCT)
The intervention showed no clear difference in severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants:… (low certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3063(3 RCTs)
The intervention showed no clear difference in ACQ responders at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (low certainty).
1 finding from 1 review